In the news release, Data from CytomX's Probody™ Pipeline to be
Presented at the 2015 AACR-NCI-EORTC International Conference on
Molecular Targets and Cancer Therapeutics, issued 26-Oct-2015 by CytomX Therapeutics over PR
Newswire, we are advised by the company that the second Abstract
title should read, "Abstract title: Development of a Probody™ Drug
Conjugate (PDC) Against CD166 for the Treatment of Multiple
Cancers", rather than "Abstract title: Development of a Probody™
Drug Conjugate (PC) Against CD166 for the Treatment of Multiple
Cancers" as originally issued inadvertently. The complete,
corrected release follows:
Data from CytomX's Probody™ Pipeline to be Presented at the 2015
AACR-NCI-EORTC International Conference on Molecular Targets and
Cancer Therapeutics
SOUTH SAN FRANCISCO, Calif.,
Oct. 26, 2015 /PRNewswire/
-- CytomX Therapeutics (Nasdaq: CTMX), a biopharmaceutical
company developing Probody™ therapeutics for the treatment of
cancer, today announced that preclinical results from its Probody
therapeutics pipeline have been accepted for presentation at the
2015 AACR-NCI-EORTC International Conference on Molecular Targets
and Cancer Therapeutics. The conference will take place
November 5-9 at the Hynes Convention
Center in Boston.
Therapeutics developed with CytomX's Probody platform are
designed to be active in the tumor while sparing healthy tissue.
This design is intended to avoid the toxicities that have been seen
with many potent cancer therapies. CytomX's preclinical pipeline of
wholly-owned and partnered programs includes Probody cancer
immunotherapies, Probody drug conjugates and Probody
bispecifics.
Abstracts to be
presented at the 2015 AACR-NCI-EORTC International
Conference
|
1.
|
Abstract
title: CD3-EGFR Bispecific Probody™ Therapeutics
Induced Tumor Regressions and Increased Therapeutic Window in
Preclinical Studies
|
|
• Friday, November 6
|
|
• 12:15
p.m. to 3:15 p.m. EST
|
|
•
Exhibit Hall C-D
|
2.
|
Abstract
title: Development of a Probody™ Drug Conjugate (PDC)
Against CD166 for the Treatment of Multiple Cancers
|
|
•
Sunday, November 8
|
|
• 12:30
p.m. to 3:30 p.m. EST
|
|
•
Exhibit Hall C-D
|
Investor Event and Webcast
CytomX will host a live event with webcast on Sunday, November 8, at approximately 6:30 p.m. EST to review the data being presented
at the conference and provide a business and pipeline update. The
webcast can be accessed live or in archived form under "News &
Events" in the Investors & News section of the company's
website at www.cytomx.com.
About CytomX Therapeutics
CytomX is an oncology-focused biopharmaceutical company pioneering
a novel class of investigational antibody therapeutics based on its
Probody technology platform. The company uses the platform to
create development-stage proprietary cancer immunotherapies against
clinically-validated targets, as well as to develop first-in-class
investigational cancer therapeutics against novel targets.
CytomX believes that its Probody platform has the potential to
improve the combined efficacy and safety profile of monoclonal
antibody modalities, including cancer immunotherapies, antibody
drug conjugates and T-cell-recruiting bispecific antibodies.
Probody therapeutics are designed to take advantage of unique
conditions in the tumor microenvironment to enhance the
tumor-targeting features of an antibody and reduce drug activity in
healthy tissues. Probody therapeutics are being developed that
address clinically-validated cancer targets in immuno-oncology,
such as PD-L1, as well as novel targets, such as CD166, that are
difficult to drug without causing damage to healthy tissues, or
toxicities. In addition to its proprietary programs, CytomX is
collaborating with strategic partners including Bristol-Myers
Squibb Company, Pfizer Inc. and ImmunoGen, Inc. For more
information, visit www.cytomx.com.
Forward-Looking Statements
This press release includes forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties and other important factors that are difficult to
predict, may be beyond our control, and may cause the actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied in such statements. Accordingly, you should not rely on any
of these forward-looking statements. Our Probody therapeutics are
in preclinical development, and the process by which a preclinical
technology could potentially lead to an approved product is long
and subject to significant risks and uncertainties. Applicable
risks and uncertainties include those relating to our preclinical
research and development and other risks identified under the
heading "Risk Factors" included in our filings with the SEC. The
forward-looking statements contained in this press release are
based on information currently available to CytomX and speak only
as of the date on which they are made. CytomX does not undertake
and specifically disclaims any obligation to update any
forward-looking statements, whether as a result of any new
information, future events, changed circumstances or otherwise.
Media Contacts:
Canale Communications
Ian Stone
ian@canalecomm.com
619-849-5388
Investor Contacts:
Trout Group
Pete Rahmer
prahmer@troutgroup.com
646-378-2973
Logo - http://photos.prnewswire.com/prnh/20150617/223685LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/data-from-cytomxs-probody-pipeline-to-be-presented-at-the-2015-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-300166141.html
SOURCE CytomX Therapeutics